- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
FDA Approves New Ebola Test for Emergency Use
The FDA has provided Emergency Use Authorization, a pre-approval for use in bad outbreaks, for Roche's new Ebola test, the LightMix Ebola Zaire rRT-PCR Test.
The FDA has provided Emergency Use Authorization, a pre-approval for use in bad outbreaks, for Roche's new Ebola test, the LightMix Ebola Zaire rRT-PCR Test.
The test, which works by detecting the signs of the Ebola virus on a genetic level, works in about three hours. There are sevenral other rRT-PCR tests that also detect the virus at a genetic level and have received this kind of emergency approval from the FDA. Since they detect the DNA of the virus, they're very accurate.
Why approve multiple tests? The consoles that run these kinds of diagnostics are expensive, so a brand-specific test might not be universally usable by hospitals around the US.
Read more at The Washington Post: http://wapo.st/1HWiUuG
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Muscle-Directed Therapy Apitegromab Meets Primary End Point in Phase 3 SAPPHIRE Trial of SMA
October 17th 2024Patients aged 2-21 receiving apitegromab showed clinically meaningful motor function improvements, with a favorable safety profile consistent with long-term data, as Scholar Rock prepares for US and EU regulatory submissions in Q1 2025.
Read More
